This is a StreetInsider.com Premium Only Page

(CRNX) – StreetInsider.com Reports

Mar 20, 2024 07:36 AM Crinetics (CRNX) PT Raised to $55 at Oppenheimer

Mar 20, 2024 06:39 AM Crinetics (CRNX) PT Raised to $60 at H.C. Wainwright

Mar 20, 2024 03:46 AM Crinetics (CRNX) PT Raised to $80 at JMP Securities, 'Paltusotine is Faster, Better, and More Convenient'

Mar 19, 2024 01:30 PM Crinetics (CRNX) PT Raised to $56 at Jones Trading

Mar 19, 2024 06:00 AM Crinetics Pharmaceuticals (CRNX) Reports paltusotine met Primary and All Secondary Endpoints

Mar 13, 2024 05:58 AM Crinetics (CRNX) PT Raised to $54 at Oppenheimer

Mar 13, 2024 05:40 AM Crinetics (CRNX) PT Raised to $47 at JPMorgan

Mar 12, 2024 04:06 PM Crinetics (CRNX) Announces Positive Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid Syndrome

Mar 8, 2024 06:33 AM Crinetics (CRNX) PT Raised to $50 at H.C. Wainwright

Mar 6, 2024 03:59 AM Citi Starts Crinetics (CRNX) at Buy, Opens 30-Day Upside Catalyst Watch, 'Upcoming Paltusotine Catalysts Primed to Drive Upside'

Mar 4, 2024 06:36 AM Crinetics (CRNX) PT Raised to $65 at Cantor Fitzgerald

Feb 29, 2024 07:39 AM Crinetics (CRNX) PT Raised to $48 at Oppenheimer

Feb 29, 2024 06:54 AM Crinetics (CRNX) PT Raised to $52 at Baird

Feb 29, 2024 03:57 AM Crinetics (CRNX) PT Raised to $60 at JMP Securities

Feb 28, 2024 04:57 PM Crinetics Pharmaceuticals (CRNX) Misses Q4 EPS by 4c

Feb 28, 2024 08:00 AM Crinetics Pharmaceuticals (CRNX) Announces 8.33M Share Offering at $42/sh

Feb 12, 2024 06:53 AM Crinetics (CRNX) PT Raised to $54 at Evercore ISI

Jan 16, 2024 04:55 AM Morgan Stanley Starts Crinetics (CRNX) at Overweight

Dec 20, 2023 04:39 PM Jefferies Starts Crinetics (CRNX) at Hold

Dec 20, 2023 06:41 AM Crinetics (CRNX) PT Raised to $42 at H.C. Wainwright

Dec 18, 2023 04:05 PM Crinetics Pharmaceuticals (CRNX) Reports Positive Initial Findings from Ongoing Open-Label Phase 2 Study of Paltusotine

Dec 5, 2023 03:55 AM Increasing unusual call option volume

Nov 20, 2023 03:59 AM JPMorgan Reinstates Crinetics (CRNX) at Overweight

Nov 7, 2023 05:39 PM Crinetics Pharmaceuticals (CRNX) Misses Q3 EPS by 14c

Oct 24, 2023 06:34 AM Cantor Fitzgerald Assumes Crinetics (CRNX) at Overweight

Sep 13, 2023 05:38 AM Crinetics Pharmaceuticals (CRNX) Prices Upsized 11.44M Share Offering at $30.59/sh

Sep 11, 2023 04:01 PM Crinetics Pharmaceuticals (CRNX) to offer $250 million in common stock

Sep 11, 2023 02:39 PM Crinetics (CRNX) PT Raised to $52 at Cantor Fitzgerald

Sep 11, 2023 10:16 AM Crinetics shares surge after "positive" hormonal disorder drug trial results

Sep 11, 2023 10:03 AM Crinetics (CRNX) PT Raised to $56 at JMP Securities, 'our top pick into the end of the year'

Sep 11, 2023 07:51 AM Crinetics (CRNX) PT Raised to $46 at Oppenheimer

Sep 11, 2023 06:58 AM Crinetics' (CRNX) Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-1 Study Evaluating Treatment of Patients with Acromegaly

Sep 11, 2023 06:43 AM Crinetics (CRNX) PT Raised to $45 at Baird

Sep 11, 2023 04:37 AM Crinetics (CRNX) PT Raised to $48 at Evercore ISI

Aug 30, 2023 04:03 PM Oppenheimer Starts Crinetics (CRNX) at Outperform, 'Building Endocrine Medicine's Future, One Small Molecule at a Time'

Aug 9, 2023 07:32 AM Crinetics (CRNX) PT Lowered to $43 at Baird

Aug 9, 2023 03:15 AM Crinetics (CRNX) PT Lowered to $42 at JMP Securities

Aug 8, 2023 08:08 AM Crinetics Pharmaceuticals (CRNX) Misses Q2 EPS by 7c

Jun 21, 2023 08:02 AM Crinetics Pharma (CRNX) Announces New Data Demonstrating Stable Biochemical and Symptom Levels with Two-Years of Oral Paltusotine Administration Presented at ENDO

May 5, 2023 02:21 AM Crinetics (CRNX) PT Raised to $43 at JMP Securities

Apr 24, 2023 03:36 AM Piper Sandler Starts Crinetics (CRNX) at Overweight

Apr 21, 2023 06:58 AM Crinetics (CRNX) PT Lowered to $35 at JPMorgan

Mar 29, 2023 04:20 PM Baird Starts Crinetics (CRNX) at Outperform

Mar 1, 2023 01:59 AM Crinetics (CRNX) PT Lowered to $41 at JMP Securities

Nov 28, 2022 08:09 AM Crinetics Pharmaceuticals (CRNX) says proposed Phase 2 clinical study on CRN04777 was not yet permitted to proceed

Oct 6, 2022 08:02 AM Crinetics Pharmaceuticals (CRNX) Granted Innovation Passport for CRN04777

Sep 2, 2022 02:46 AM Crinetics (CRNX) PT Raised to $52 at JMP Securities

May 25, 2022 07:02 AM Crinetics Pharmaceuticals (CRNX) Reports Positive Top-line Results Including Strong Adrenal Suppression from CRN04894 Phase 1 Study

Apr 13, 2022 05:39 AM Crinetics Pharmaceuticals (CRNX) Prices 5.63M Share Offering at $22.22/sh

Mar 31, 2022 02:42 AM Crinetics (CRNX) PT Raised to $45 at JMP Securities